Home » Stocks » ARGX

Argenx SE (ARGX)

Stock Price: $279.22 USD -2.95 (-1.05%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 13.24B
Revenue (ttm) 78.41M
Net Income (ttm) -183.11M
Shares Out 38.62M
EPS (ttm) -1.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $279.22
Previous Close $282.17
Change ($) -2.95
Change (%) -1.05%
Day's Open 279.58
Day's Range 278.02 - 282.86
Day's Volume 163,237
52-Week Range 108.83 - 308.36

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 1 week ago

Gracell Biotech completed a $209 million NASDAQ IPO for its next-gen CAR-T treatments. Zai Lab acquired greater China rights to an argenx SE novel treatment for autoimmune indications in a dea...

Other stocks mentioned: EYPT, GILD, GRCL, INO, LLY, PRTK, ZLAB
GlobeNewsWire - 1 week ago

Breda, the Netherlands – Jan. 8, 2021 – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and c...

GlobeNewsWire - 1 week ago

January 4, 2021 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimm...

GlobeNewsWire - 1 month ago

November 23, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoi...

PRNewsWire - 2 months ago

BREDA, the Netherlands and GHENT, Belgium, Nov. 17, 2020 /PRNewswire/ -- argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from...

GlobeNewsWire - 2 months ago

November 9, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoim...

Seeking Alpha - 2 months ago

argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q3 2020 Results - Earnings Call Transcript

Benzinga - 2 months ago

Shares of argenx (NASDAQ:ARGX) decreased 6.1% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 450.00% year over year to ($3.96), whi...

GlobeNewsWire - 2 months ago

- Biologics License Application (BLA) for efgartigimod in generalized myasthenia gravis (gMG) on track to be submitted to U.S. Food and Drug Administration (FDA) by end of 2020 -

GlobeNewsWire - 3 months ago

October 15, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoim...

Seeking Alpha - 3 months ago

Argenx: Competitive Positioning In The GMG Space

GlobeNewsWire - 3 months ago

             

GlobeNewsWire - 3 months ago

             

GlobeNewsWire - 4 months ago

September 2, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe au...

GlobeNewsWire - 5 months ago

August 4, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoi...

Seeking Alpha - 5 months ago

argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

July 30, 2020 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoim...

Benzinga - 5 months ago

On Thursday, July 30, argenx (NASDAQ: ARGX) will release its latest earnings report.

Zacks Investment Research - 6 months ago

argenx (ARGX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

GlobeNewsWire - 7 months ago

Regulated information

GlobeNewsWire - 7 months ago

Regulated information — Inside information

GlobeNewsWire - 7 months ago

Regulated information — Inside information

Zacks Investment Research - 7 months ago

argenx's (ARGX) lead pipeline candidate, efgartigimod, meets primary endpoint in a pivotal study evaluating it in myasthenia gravis. A BLA is likely to be filed by the end of 2020.

GlobeNewsWire - 7 months ago

Regulated information — Inside information

The Motley Fool - 7 months ago

Positive pivotal trial results are giving investors a reason to cheer.

GlobeNewsWire - 7 months ago

Regulated information – Inside information

Seeking Alpha - 8 months ago

argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q1 2020 Results - Earnings Call Transcript

GlobeNewsWire - 8 months ago

            - Topline data readout from Phase 3 ADAPT trial of efgartigimod in generalized myasthenia gravis on track for mid-2020 and Biologics License Application filing by end of year -    ...

InvestorPlace - 8 months ago

Amid the COVID-19 pandemic, the investing pros say that it’s still possible to unmask names poised to take off on an upward trajectory.

Other stocks mentioned: ASND, AXSM, FOLD, IOVA, NTRA, UTHR
Seeking Alpha - 9 months ago

Market Fairly Evaluates Argenx's Efgartigimod (ARGX-113) In Myasthenia Gravis

Seeking Alpha - 10 months ago

Argenx: The Upside Is Still There

Seeking Alpha - 10 months ago

argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

Top Ranked Momentum Stocks to Buy for February 27th

Other stocks mentioned: ADNT, DDOG, KNSL
GlobeNewsWire - 10 months ago

             

Zacks Investment Research - 10 months ago

argenx (ARGX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

24/7 Wall Street - 1 year ago

The American Society of Hematology (ASH) hosted its 61st annual meeting, and one of the biggest biotech events, earlier this week in Orlando, Florida.

Other stocks mentioned: BLUE, BPMC, EPZM, FATE, MGTA
GlobeNewsWire - 1 year ago

Regulated information – Inside information

GlobeNewsWire - 1 year ago

Regulated information – Inside information

The Motley Fool - 1 year ago

Biotechs trade on the prospects of new advancements to identify and treat diseases. That's something the world needs in good times and bad.

Other stocks mentioned: GLPG, NVCR
Seeking Alpha - 1 year ago

Shares have risen by 385% since my initial recommendation and by 120% since my last update.

GlobeNewsWire - 1 year ago

September 3, 2019

Seeking Alpha - 1 year ago

argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Does ARGENX SE-ADR (ARGX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Seeking Alpha - 1 year ago

argenX unveiled two new pipeline candidates in May.

About ARGX

argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis in Phase 3; immune thrombocytopenia in Phase 3; pemphigus vulgaris in Phase 2; chronic inflammatory demyelinating polyneuropathy in Phase 2; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase 2 clinical stage in hematological cancer i... [Read more...]

Industry
Biotechnology
IPO Date
May 18, 2017
CEO
Tim Van Hauwermeiren
Employees
186
Stock Exchange
NASDAQ
Ticker Symbol
ARGX
Full Company Profile

Financial Performance

In 2019, Argenx SE's revenue was 69.78 million, an increase of 224.84% compared to the previous year's 21.48 million. Losses were -162.97 million, 144.5% more than in 2018.

Financial numbers in millions EUR.
Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for Argenx SE is 304.30, which is an increase of 8.98% from the latest price.

Price Target
$304.30
(8.98% upside)